Global Coalition for Adaptive Research

Are you interested in learning more about operationalizing master protocols? ?? ? Check out our latest white paper, ‘Operationalizing Master Protocols: Insights, Strategies, and Future Perspectives’ by visiting: https://gcaresearch.org We are sharing our insights with the goal of helping others to integrate these solutions into their operational models. We aim to create lasting value for those involved in master protocol implementation as well as for clinical research more broadly. At GCAR, we believe that active collaboration can lead to better efficiency, higher quality, faster growth, and promising new opportunities. We are #FasterTogether! ?? #ClinicalTrials #MasterProtocols #Innovation #WhitePapers #ClinicalResearch

We're thrilled to share valuable insights and actionable solutions with our latest white papers! Our first two papers dive into master protocols, highlighting benefits to stakeholders and key operational considerations for these specialized trials. Stay tuned – we’ll be releasing more white papers in the coming months, covering topics like site activation & engagement, data management, financial efficiency, and resourcing. We are eager to continue to educate and raise awareness about these innovative clinical trial solutions, with the goal of elevating and engaging the broader community. We are #FasterTogether! To read our latest white papers, visit: https://lnkd.in/ggH7b_9D #ClinicalTrials #MasterProtocols #Innovation #WhitePapers #ClinicalResearch

There are 300 million people worldwide living with a?#raredisease. GCAR is committed to helping patients with?#rarediseases?by making?#clinicaltrials?more efficient. Our goal is to learn faster by uniting stakeholders and delivering innovative trials that accelerate the time from discovery in the lab to implementation in the clinic resulting in better treatments and lives saved. Our cornerstone clinical trial,?#GBMAGILE?evaluates therapies for patients with newly diagnosed and recurrent?#glioblastoma. Although classified as rare, glioblastoma is the most common and aggressive primary brain tumor in adults. New initiatives are underway for other rare diseases and cancers including?#ovariancancer?#biliarytractcancer?#neurofibromatosis?and?#pancreaticcancer?through collaboration with patient advocacy partners, clinical leadership, and pharma. #RareDiseaseDay?#clinicaltrials?#FasterTogether

Earlier this week, GCAR staff members had the pleasure of meeting Cheryl Waye, a devoted brain cancer advocate. She shared her daughter, Alysha’s story with us. After Alysha’s diagnosis with #glioblastoma,?Alysha and Cheryl founded Alysha’s Army to raise awareness and funding for brain cancer research and patient support services. We surprised Cheryl by wearing purple in honor of the ‘Purple Day’ fundraiser that she hosts each February to celebrate Alysha and to raise funds for vital research. Thank you, Cheryl, for your tireless efforts to create positive change for families affected by brain tumors ?? ??

February 20 is World Cholangiocarcinoma Day! ?? We are honored to team up with the Cholangiocarcinoma Foundation (CCF) to raise awareness about?#cholangiocarcinoma, a rare cancer of the bile duct. In collaboration with CCF, GCAR is sponsoring the development and implementation of an innovative?#clinicaltrial?for patients with biliary tract cancer. This master protocol trial is designed to enhance efficiency while offering a more?#patientcentric?approach that improves access to new treatment options. To learn more about the Biliary Tract Cancer Master Protocol, visit: https://lnkd.in/gx426hTP To learn more about CCF's patient support services, education, and research, visit: https://lnkd.in/erHzRWzu Let’s make a difference together!?#GreenforCCA?#WorldCCADay

Going to the Glioblastoma Drug Development Summit? Connect with us to learn more about opportunities to evaluate therapies in #GBMAGILE– an efficient, patient-centric, accelerated drug development solution that maximizes learning. With some of the world’s foremost clinical, translational, and basic science investigators and experts in developing and operationalizing master protocols and platform trials, GCAR is committed to improving outcomes for patients with rare and deadly diseases like #glioblastoma. We invite you to learn more and meet our team. Email us at [email protected] Let's make progress #together!

We are excited to announce the expansion of Rob Murray's role to Chief Business and Strategy Officer at GCAR! ?? This broadened role combines strategy and business leadership, ensuring our efforts to align our vision with execution. Rob will help us navigate market trends, build key partnerships, and drive growth in innovative clinical research for rare and deadly diseases. His leadership will ensure we stay agile and deliver on our goals with impact. #Leadership #Innovation #StrategicGrowth

We are thrilled to announce that the U.S. Department of Defense has selected GCAR to be the regulatory lead for an adaptive platform trial that is evaluating multiple pharmacotherapeutic interventions for the treatment of posttraumatic stress disorder (PTSD). The Military and Veterans PTSD Adaptive Platform Clinical Trial (M-PACT) is recruiting active-duty service members and veterans with PTSD at multiple clinical sites and is supported by a project team that includes representatives from the U.S. Air Force, Army, Navy, and Special Operations Command. M-PACT is recruiting patients at trial locations in: - Miami, FL - Atlanta, GA - Fort Thomas, KY - Williamsville, NY - Joint Base Lewis McChord, WA Additional trial locations to open in the coming months. To read the full announcement, visit: https://lnkd.in/gGqWtkcV If you are interested in participating in this study, visit: https://lnkd.in/gEeTBzdk For additional trial information, visit: https://lnkd.in/eccCAqFw #PTSD #ClinicalTrial #Military #ActiveDuty #Veterans

Thank you Meira Spivak?? for your insights and coaching. We appreciate the opportunity to work together - driving innovation and reaching creative solutions that help us to further our mission of advancing treatments for those affected by rare and deadly diseases. Looking forward to our next session!?#Innovation #ClinicalTrials #Collaboration

Today is #WorldCancerDay! ?? ?? At GCAR, we are unwavering in our commitment to fighting some of the most rare and deadly cancers. Our mission is clear: to accelerate the development of more effective treatments for these devastating diseases and bring hope to those who need it most. While survival rates for rare cancers vary significantly depending on the cancer type and stage at diagnosis, rare cancers often have worse outcomes compared to more common cancers. The reasons for this include later diagnoses, limited treatment options, and a lack of large-scale clinical trials . Clinical trials are essential to discovering new and better ways to treat these cancers. That's why GCAR is prioritizing some of the most aggressive and deadly cancers, including #Glioblastoma, #PancreaticCancer, #OvarianCancer, and #BiliaryTractCancer (#Cholangiocarcinoma). By leading innovative trials, such as #MasterProtocols and #AdaptivePlatformTrials, we are modernizing the clinical trial process. Our goal is to accelerate the time from groundbreaking research in the lab to real-world treatments in the clinic. This means more efficient drug development, quicker access to new therapies, and ultimately, more lives saved. Today, we stand with patients, researchers, and advocates across the globe in the fight against cancer. Together, we can make a difference. ?? Learn more about our trials and how GCAR is making a difference for #cancer patients at https://GCAResearch.org #CancerResearch #ClinicalTrials #InnovationInHealth #FasterTogether